Industry is gathering scientific data to approach the regulator, DCGI, for a review of the suspension order.
GVK Biosciences is the latest Indian firm to come under international scrutiny over quality issues.
Major losers include Lupin 1.96 per cent, along with Tata Motors, Coal India and Sun Pharma.
Novartis said it is partnered with generic drugmaker Lupin Ltd to sell the drug in India
Ajit Mishra, vice president, Research, Religare Broking, answers your queries
Consumer businesses come to the rescue of large conglomerates in the midst of a meltdown in commodities.
Rosier year-end seen for Indian pharma thanks to faster US approvals.
Shree Cement beats ACC in market value, Lupin ahead of Dr Reddy's Labs
The Commonwealth gold medallist said that women must focus on developing their inner strength.
Once tipped to emerge as the biggest exporter, the pharmaceutical industry is yet to acquire the scale of those in software services, says Krishna Kant.
While sales in the domestic market declined 4.2 per cent during the April-July period, exports grew steadily at 9.5 per cent during the same period.
The list acknowledges the 'inroads women are making in the business world'.
Media tycoon Kalanithi Maran and his wife Kavery Kalanithi have retained the top two slots among the highly paid executives in the country.
Indian auto and pharma industries import several critical components and raw materials from China.
Indian loses chance to be research hub as domestic drug companies move R&D overseas.
Currently, the investor and his family's net worth in listed firms stands at Rs 8,517 crore, compared to Rs 8,388 crore as of March 31, 2020.
In the US, the ratio of the CEO to average worker pay ratio was 373:1 in 2014.
Companies which have been dropped from the list include Tata Motors, Hindustan Unilever, MRF, Glaxo SmithKline Consumer Healthcare, Pfizer, Dr Reddy's Labs, Glenmark Pharmaceuticals, HDFC and Kotak Mahindra Bank
Participants will watch out for the Brexit poll outcome in the late morning trades tomorrow.
The turmoil on the Street and a continued fall of the rupee may affect growth stocks, pushing equity investors back to the relative safety of defensive counters, or forcing them to flee markets, or both.
Who do you think can be cast in the desi version of Harry Potter?
Not much is heard or read about Sun Pharma's media-shy owner.
Samina Vaziralli, daughter of joint Managing Director M K Hamied, was inducted into the company management. Cipla joins the league of major companies such as Lupin, Wockhardt, Elder Pharma, Piramal Healthcare and JB Chemicals in this regard.
Forbes said Prime Minister Narendra Modi's "economic experiments" barely affected India's billionaires while none gained more than oil-and-gas tycoon Mukesh Ambani, who cemented his decade-long hold on the top slot by adding a staggering USD 15.3 billion (67 per cent) to his last year's wealth to become one of Asia's top five richest.
Currently, the govt directly caps prices of 348 formulations at the average price of all medicines in a particular segment with at least 1% market share
The brokerage said it expected corporate earnings to turn around.
Over 550,000 small drug retailers in the country are transforming into producers and marketers of pharmaceutical products, readying to compete with companies such as Ranbaxy, Cipla, Sun Pharma and Lupin whose produce they sell.
According to industry estimates, the sector's revenue would increase eight-10 per cent in 2013-14, against 12 per cent in 2012-13.
Regulators tighten net on safety grounds.
This analysis is based on the quarterly earnings for 724 companies.
With an m-cap of Rs 31,744 crore, IRCTC stood at 96th position in the overall market capitalisation ranking, the BSE data shows.
Ten months after new Sebi norms set in, some senior directors still hold more board seats than allowed.
Analysts now expect India Inc to report a decline in both top line and bottom line for the September quarter.
A six-member jury headed by former Securities and Exchange Board of India chairman M Damodaran will declare the winner of the award for 2009 on February 16 in Mumbai.
Sun Pharma stock has appreciated at 35% a year for 20 years
Under MRA, Japan is to recognise Indian medical degrees and treat the country's doctors and other medical personnel on par with its own.
Tata Motors (down 1.7%) was the top loser on Sensex and Nifty, while Lupin (1.6%) gained the most.
Infosys was the top Sensex loser along with other index heavyweights ITC and HDFC.
Generic drug sales in the US, that power the business of such leading Indian drug manufacturers as Ranbaxy, Dr Reddy's, Sun Pharma, Lupin and Zydus Cadila, will face competition soon, as big US wholesalers decide to outsource their requirements from upcoming Indian manufacturers.
After a volatile session, Sensex closed the day 563 points lower
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances